CN100393356C - 用于癌症治疗的经修饰的细胞因子 - Google Patents
用于癌症治疗的经修饰的细胞因子 Download PDFInfo
- Publication number
- CN100393356C CN100393356C CNB2003801078431A CN200380107843A CN100393356C CN 100393356 C CN100393356 C CN 100393356C CN B2003801078431 A CNB2003801078431 A CN B2003801078431A CN 200380107843 A CN200380107843 A CN 200380107843A CN 100393356 C CN100393356 C CN 100393356C
- Authority
- CN
- China
- Prior art keywords
- tnf
- ngr
- ifn
- tumor
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (23)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/287,811 | 2002-11-05 | ||
US10/287,811 US7309694B2 (en) | 2000-02-15 | 2002-11-05 | Modified cytokines for use in cancer therapy |
US10/426,019 US7109303B2 (en) | 2000-02-15 | 2003-04-30 | Modified cytokines for use in cancer therapy |
US10/426,019 | 2003-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1732016A CN1732016A (zh) | 2006-02-08 |
CN100393356C true CN100393356C (zh) | 2008-06-11 |
Family
ID=32314357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003801078431A Expired - Fee Related CN100393356C (zh) | 2002-11-05 | 2003-11-05 | 用于癌症治疗的经修饰的细胞因子 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7109303B2 (zh) |
EP (1) | EP1562620B1 (zh) |
JP (1) | JP4761963B2 (zh) |
CN (1) | CN100393356C (zh) |
AT (1) | ATE431742T1 (zh) |
AU (1) | AU2003283699B2 (zh) |
CA (1) | CA2504963C (zh) |
DE (1) | DE60327710D1 (zh) |
ES (1) | ES2326530T3 (zh) |
WO (1) | WO2004041297A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7612194B2 (en) * | 2001-07-24 | 2009-11-03 | Monsanto Technology Llc | Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof |
GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
GB0312309D0 (en) * | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
WO2006067633A2 (en) * | 2004-12-23 | 2006-06-29 | Molmed Spa | Conjugation product |
GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
CA2723823C (en) * | 2008-05-13 | 2012-10-16 | Molmed S.P.A. | Conjugates for the treatment of mesothelioma |
US20130150566A1 (en) * | 2011-07-06 | 2013-06-13 | Targetpharma Laboratories (Changzhou) Co., Ltd | Tumor-targeted tnf-related apoptosis-inducing ligand's variant and the application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001061017A2 (en) * | 2000-02-15 | 2001-08-23 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3423234A1 (de) | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
US4650674A (en) | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
IT1245748B (it) | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5258517A (en) | 1992-08-06 | 1993-11-02 | Sepracor, Inc. | Method of preparing optically pure precursors of paroxetine |
WO1995015979A1 (en) | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
US5888814A (en) | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
AU4412297A (en) | 1996-09-10 | 1998-04-02 | Burnham Institute, The | Tumor homing molecules, conjugates derived therefrom, and methods of using sa me |
US6576239B1 (en) * | 1996-09-10 | 2003-06-10 | The Burnham Institute | Angiogenic homing molecules and conjugates derived therefrom |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
EP1015884B1 (en) | 1997-09-10 | 2008-08-06 | The Burnham Institute | Methods of identifying molecules that home to angiogenic vasculature in tumors |
US6180084B1 (en) | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
-
2003
- 2003-04-30 US US10/426,019 patent/US7109303B2/en not_active Expired - Fee Related
- 2003-11-05 JP JP2005502144A patent/JP4761963B2/ja not_active Expired - Fee Related
- 2003-11-05 ES ES03775680T patent/ES2326530T3/es not_active Expired - Lifetime
- 2003-11-05 DE DE60327710T patent/DE60327710D1/de not_active Expired - Lifetime
- 2003-11-05 EP EP03775680A patent/EP1562620B1/en not_active Expired - Lifetime
- 2003-11-05 CN CNB2003801078431A patent/CN100393356C/zh not_active Expired - Fee Related
- 2003-11-05 AU AU2003283699A patent/AU2003283699B2/en not_active Ceased
- 2003-11-05 WO PCT/IB2003/005657 patent/WO2004041297A2/en active Application Filing
- 2003-11-05 CA CA2504963A patent/CA2504963C/en not_active Expired - Fee Related
- 2003-11-05 AT AT03775680T patent/ATE431742T1/de not_active IP Right Cessation
-
2006
- 2006-01-25 US US11/338,842 patent/US7622105B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001061017A2 (en) * | 2000-02-15 | 2001-08-23 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
Non-Patent Citations (4)
Title |
---|
Interferon gamma and tumor necrosis factor alpha synergismin ME-80 cervical cancer cell apoptosis and necrosis. SUK K ET AL.THE JOURNAL OF BIOLOGICAL CHEMISTRY,Vol.276 No.6. 2001 |
Interferon gamma and tumor necrosis factor alpha synergismin ME-80 cervical cancer cell apoptosis and necrosis. SUK K ET AL.THE JOURNAL OF BIOLOGICAL CHEMISTRY,Vol.276 No.6. 2001 * |
TARGETED DELIVERY OF TUMOR NECROSIS FACTORALPHA TO TUMOR ASSOCIATED VESSELS. CURNIS F ET AL.INTERNATIONSL ANJOURNAL OF MOLECULAR MEDICINE,Vol.6 No.SUPPL 1. 2000 |
TARGETED DELIVERY OF TUMOR NECROSIS FACTORALPHA TO TUMOR ASSOCIATED VESSELS. CURNIS F ET AL.INTERNATIONSL ANJOURNAL OF MOLECULAR MEDICINE,Vol.6 No.SUPPL 1. 2000 * |
Also Published As
Publication number | Publication date |
---|---|
JP4761963B2 (ja) | 2011-08-31 |
JP2006514984A (ja) | 2006-05-18 |
EP1562620A2 (en) | 2005-08-17 |
US7622105B2 (en) | 2009-11-24 |
CA2504963C (en) | 2013-09-03 |
DE60327710D1 (de) | 2009-07-02 |
US20060115451A1 (en) | 2006-06-01 |
CA2504963A1 (en) | 2004-05-21 |
ATE431742T1 (de) | 2009-06-15 |
AU2003283699A1 (en) | 2004-06-07 |
CN1732016A (zh) | 2006-02-08 |
ES2326530T3 (es) | 2009-10-14 |
AU2003283699B2 (en) | 2009-11-19 |
EP1562620B1 (en) | 2009-05-20 |
US20040018171A1 (en) | 2004-01-29 |
WO2004041297A2 (en) | 2004-05-21 |
WO2004041297A3 (en) | 2004-07-29 |
US7109303B2 (en) | 2006-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7476721B2 (en) | Modified cytokines for use in cancer therapy | |
US20050074426A1 (en) | Fusions of cytokines and tumor targeting proteins | |
EP1499730B1 (en) | Immunoconjugates for the treatment of tumours | |
JP2008525424A (ja) | 複合生成物 | |
US7622105B2 (en) | Modified cytokines for use in cancer therapy | |
WO2008152508A2 (en) | Cytokine conjugate | |
US7309694B2 (en) | Modified cytokines for use in cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENGLAI FALAI HOSPITAL CO., LTD. Free format text: FORMER OWNER: TABOR FUND CENTER Effective date: 20130819 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: TABOR FUND CENTER Free format text: FORMER NAME: FONDAZIONE CENTRO SAN RAFFACLE DEL MONTE TABOR |
|
CP01 | Change in the name or title of a patent holder |
Address after: Milan Italy Patentee after: Tabor hills fund center Address before: Milan Italy Patentee before: San Rafael del Monte Tabo Fund Center |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130819 Address after: Milan Italy Patentee after: San rafael hospital Co.,Ltd. Address before: Milan Italy Patentee before: Tabor hills fund center |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080611 Termination date: 20181105 |
|
CF01 | Termination of patent right due to non-payment of annual fee |